Description
Irinotecan Medak for Infusions 20 mg/ml – 15 ml (300 mg)
Composition
Active Ingredient: Irinotecan hydrochloride trihydrate
Mechanism of Action
Irinotecan is a topoisomerase I inhibitor that disrupts DNA replication and cell division in cancer cells, ultimately leading to cell death.
Pharmacological Properties
Irinotecan Medak for infusions has demonstrated efficacy in treating various solid tumors, particularly colorectal cancer. It exhibits synergistic effects when combined with other chemotherapy agents.
Indications for Use
Irinotecan Medak for infusions is indicated for:
- Colorectal cancer
- Small cell lung cancer
- Pancreatic cancer
Contraindications
Do not use Irinotecan Medak for infusions if:
- You are allergic to irinotecan or any other ingredients
- You have a history of severe bone marrow suppression
- You experience severe diarrhea
Side Effects
Common side effects may include nausea, vomiting, diarrhea, and myelosuppression. It is essential to monitor for potential adverse reactions during treatment.
Usage Instructions
Dosage: The recommended dose is based on the patient’s body surface area and overall health status. Administer intravenously over 90 minutes under healthcare professional supervision.
Benefits Compared to Analogues
Irinotecan Medak for infusions offers superior efficacy in treating colorectal, lung, and pancreatic cancers compared to traditional chemotherapy agents. Its combination therapy approach enhances treatment outcomes.
Suitable Patient Groups
Irinotecan Medak is suitable for adult patients with specific types of cancer. Dosage adjustments may be necessary for elderly or pediatric populations based on individual factors.
Storage and Shelf Life
Storage: Follow storage instructions provided in the packaging. Protect from light and store out of children’s reach. Check the expiration date before use.
Packaging Description
The product is available in a 15 ml vial containing 300 mg of Irinotecan Medak solution for infusion.
Clinical Evidence and Proven Effectiveness
Pharmacological Effects: Irinotecan’s mechanism of action has shown significant efficacy in various cancers, particularly colorectal cancer. Combination therapies have demonstrated improved outcomes in clinical settings.
Clinical Trials: Studies have confirmed the benefits of Irinotecan in enhancing progression-free and overall survival rates in advanced colorectal cancer patients. The drug’s tolerability and manageable side effect profile support its clinical utility.
Additional Information
Precautions: Regular monitoring of blood counts and liver function is crucial during treatment. Inform healthcare providers about any existing medical conditions or medications to ensure safe administration.
In conclusion, Irinotecan Medak for infusions is a well-established chemotherapy option with proven efficacy in managing various cancers. Its pharmacological properties and clinical evidence support its role in cancer therapy.
